PMID- 9708807
OWN - NLM
STAT- MEDLINE
DCOM- 19980825
LR  - 20240214
IS  - 0002-9440 (Print)
IS  - 1525-2191 (Electronic)
IS  - 0002-9440 (Linking)
VI  - 153
IP  - 2
DP  - 1998 Aug
TI  - Cellular distribution of retinoic acid receptor-alpha protein in serous 
      adenocarcinomas of ovarian, tubal, and peritoneal origin: comparison with 
      estrogen receptor status.
PG  - 469-80
AB  - Retinoids are effective growth modulators of human ovarian carcinoma cell lines. 
      Their effects are mediated by nuclear retinoic acid receptors (RARs) and retinoid 
      X receptors (RXRs), which are transcriptional factors and members of the 
      steroid/thyroid receptor superfamily. To our knowledge, until now, the cellular 
      distribution of RAR proteins in human ovarian tumor specimens is unknown. This 
      study provides new data on the differential cellular localization of RAR alpha 
      protein in 16 serous adenocarcinomas originating from the ovaries, fallopian 
      tubes, and the peritoneum. Using an affinity-purified antiserum specific for RAR 
      alpha and a monoclonal antibody recognizing the full-length estrogen receptor 
      molecule (clone 6F11), we performed immunohistochemistry on frozen tissue 
      sections and examined the relationship between RAR alpha and estrogen receptor 
      protein expression by comparing the percentage of immunostained tumor cells for 
      either receptor. Our findings indicate a strong linear relationship between the 
      percentages of RAR alpha- and estrogen receptor-labeled tumor cells as determined 
      by linear regression analysis (P < 0.005, r = 0.825). A modest inverse 
      relationship was found between the percentage of RAR alpha-positive tumor cells 
      and histological grade, attesting to a differentiation-dependent trend (P < 
      0.04). No significant relationship was found between RAR alpha-labeled cells and 
      clinical stage (P = 0.139), site of tumor origin (ovaries versus fallopian tubes 
      versus peritoneum) (P = 0.170), and primary versus metastatic lesion (P = 0.561). 
      Thus, serous adenocarcinomas are capable of expressing RAR alpha and estrogen 
      receptor despite high histological grade and advanced stage of neoplastic 
      disease. Compared with the heterogeneous localization of RAR alpha in cancer 
      cells, there was widespread RAR alpha immunoreactivity in tumor-infiltrating 
      lymphocytes, vascular endothelial cells, and stromal fibroblasts, underscoring 
      the value of immunohistochemistry in the accurate determination of RAR/(RXR) 
      content in tumor specimens.
FAU - Katsetos, C D
AU  - Katsetos CD
AD  - Department of Microbiology and Immunology, Temple University School of Medicine, 
      Philadelphia, Pennsylvania, USA. dkatseto@bellatlantic.net
FAU - Stadnicka, I
AU  - Stadnicka I
FAU - Boyd, J C
AU  - Boyd JC
FAU - Ehya, H
AU  - Ehya H
FAU - Zheng, S
AU  - Zheng S
FAU - Soprano, C M
AU  - Soprano CM
FAU - Cooper, H S
AU  - Cooper HS
FAU - Patchefsky, A S
AU  - Patchefsky AS
FAU - Soprano, D R
AU  - Soprano DR
FAU - Soprano, K J
AU  - Soprano KJ
LA  - eng
GR  - R01 CA064945/CA/NCI NIH HHS/United States
GR  - 3 RO1-CA64945-02S1/CA/NCI NIH HHS/United States
GR  - R01 CA64945/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Pathol
JT  - The American journal of pathology
JID - 0370502
RN  - 0 (RARA protein, human)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Retinoic Acid Receptor alpha)
SB  - IM
MH  - Adenocarcinoma/*metabolism/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blotting, Western
MH  - Fallopian Tube Neoplasms/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Middle Aged
MH  - Neoplasms, Cystic, Mucinous, and Serous/metabolism/pathology
MH  - Ovarian Neoplasms/*metabolism/pathology
MH  - Peritoneal Neoplasms/*metabolism/pathology
MH  - Receptors, Estrogen/*metabolism
MH  - Receptors, Retinoic Acid/*metabolism
MH  - Retinoic Acid Receptor alpha
PMC - PMC1852976
EDAT- 1998/08/26 00:00
MHDA- 1998/08/26 00:01
PMCR- 1999/02/01
CRDT- 1998/08/26 00:00
PHST- 1998/08/26 00:00 [pubmed]
PHST- 1998/08/26 00:01 [medline]
PHST- 1998/08/26 00:00 [entrez]
PHST- 1999/02/01 00:00 [pmc-release]
AID - S0002-9440(10)65590-3 [pii]
AID - 1385 [pii]
AID - 10.1016/s0002-9440(10)65590-3 [doi]
PST - ppublish
SO  - Am J Pathol. 1998 Aug;153(2):469-80. doi: 10.1016/s0002-9440(10)65590-3.